Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07517068 · ClinicalTrials.gov registry record · Early Phase 1
The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude
A Early Phase 1 study, sponsored by University of California, Riverside.
- Active
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT07517068: Active Early Phase 1 study, sponsored by University of California, Riverside.
NCT07517068 is a Early Phase 1 study that is active but no longer recruiting, run by University of California, Riverside. The registered enrollment target is 19 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07517068, a Early Phase 1 study, is active but no longer recruiting, sponsored by University of California, Riverside.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.
Primary Outcome
Distributions of peripheral leukocyte subsets in peripheral blood will be quantified at each timepoint of exposure (sea level before ascent, days 1-3 at high altitude, and days 7 and 30 following return to sea level) and in each treatment condition (placebo and ACZ). Blood samples will be collected in the morning immediately following waking, while fasting. Cell distributions will be determined via flow cytometry.
Interventions
- DEVICE Placebo Arm
- DRUG ACETAZOLAMIDE oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2026-12-15 |
| Phase | Early Phase 1 |
What the registry record for NCT07517068 still lists
NCT07517068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Arm is the first listed.
NCT07517068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07517068 about?
NCT07517068 is a clinical study titled "The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude". High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated...
What is the current status of trial NCT07517068?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2025-09-17. Estimated completion is 2026-12-15.
What interventions are being tested in trial NCT07517068?
The interventions under investigation include: Placebo Arm (DEVICE), ACETAZOLAMIDE oral capsule (DRUG).
Who is sponsoring clinical trial NCT07517068?
This trial is sponsored by University of California, Riverside, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07517068's enrollment target sits among peer trials
19 1292nd of 2000 higher than 686 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI